The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Adverum Biotechnologies, Inc. | Common Stock | 00773U108 | 6,639 | 5,068,233 | SH | OTR | 0 | 5,068,233 | 0 | ||
| Akero Therapeutics, Inc. | Common Stock | 00973Y108 | 8,766 | 617,727 | SH | OTR | 0 | 617,727 | 0 | ||
| Aligos Therapeutics, Inc. | Common Stock | 01626L105 | 4,989 | 2,320,381 | SH | OTR | 0 | 2,320,381 | 0 | ||
| Clovis Oncology, Inc. | Common Stock | 189464100 | 206 | 101,855 | SH | OTR | 0 | 101,855 | 0 | ||
| Crinetics Pharmaceuticals, Inc. | Common Stock | 22663K107 | 9,007 | 410,360 | SH | OTR | 0 | 410,360 | 0 | ||
| CRISPR Therapeutics AG | Common Shares | H17182108 | 31,294 | 498,558 | SH | OTR | 0 | 498,558 | 0 | ||
| CymaBay Therapeutics, Inc. | Common Stock | 23257D103 | 1,691 | 543,753 | SH | OTR | 0 | 543,753 | 0 | ||
| Gritstone Oncology, Inc. | Common Stock | 39868T105 | 14,672 | 3,561,150 | SH | OTR | 0 | 3,561,150 | 0 | ||
| Minerva Surgical Inc. | Common Stock | 60343F106 | 7,532 | 1,673,700 | SH | OTR | 0 | 1,673,700 | 0 | ||
| Passage Bio, Inc. | Common Stock | 702712100 | 15,375 | 4,959,769 | SH | OTR | 0 | 4,959,769 | 0 | ||